Cardiac resynchronization therapy in heart failure patients by using left bundle branch pacing
Ying Gu1, Yanming Li1, Ying Zhu1
1Department of Cardiology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
Frontiers in Cardiovascular Medicine
|September 9, 2022
Summary
Left bundle branch pacing (LBBP) is a feasible and effective treatment for heart failure patients with left bundle branch block (LBBB). This study shows LBBP significantly improves heart function and structure with stable pacing parameters.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Left bundle branch pacing (LBBP) is an emerging technique for cardiac resynchronization therapy (CRT).
- It offers a potential alternative to conventional CRT methods for improving heart function.
Purpose of the Study:
- To evaluate the feasibility and efficacy of LBBP in heart failure patients.
- Specifically targeting patients with reduced left ventricular ejection fraction (LVEF <50%) and left bundle branch block (LBBB).
Main Methods:
- Retrospective analysis of 34 patients with complete LBBB and LVEF <50% undergoing LBBP implantation for CRT.
- Data collected included ECG, pacing parameters, NYHA functional class, echocardiographic measurements, and complications.
- Analysis performed at baseline and at 1, 6, and 12 months post-implantation.
Main Results:
- Successful LBBP implantation in all 34 patients.
- Significant reduction in QRS duration (QRSd) and improvement in LVEF (from 35.3% to 51.1%) at 12 months.
- Improvements observed in NYHA class, 6-minute walk test, and reduction in cardiac dimensions; no deaths or heart failure hospitalizations.
Conclusions:
- LBBP is a feasible and highly successful implantation strategy for CRT in selected heart failure patients.
- It effectively corrects LBBB, improves left ventricular structure and function, and demonstrates stable pacing parameters.
- LBBP represents a promising approach for CRT with significant clinical benefits.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Heart Failure Drugs: β-Blockers
419
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
419
Cardiomyopathy II: Dilated Cardiomyopathy
19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy V: Interprofessional Care
29
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
29
Heart Failure Drugs: Inotropic Agents
692
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
692
Heart Failure V: Medical Management
21
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
21


